KUALA LUMPUR, March 18 -- RoosterBio Inc has announced a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company, Senti Biosciences Inc (Senti) to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumour indications.
The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and current Good Manufacturing Practices (cGMP)-compliant, hMSC-focused manufacturing capabilities.
“Gene-modified cell therapies are one of the most important segments in our industry, and we are excited to help Senti Biosciences accelerate its technology into the clinic,” said RoosterBio’s Founder & Chief Product Officer, Jon A. Rowley, PhD in a statement.
“Our collaboration reflects the importance of strategically positioned gene engineering platforms that are designed for rapid clinical translation.”
Under the terms of the agreement, Senti will apply its novel gene circuit technology to hMSCs produced by RoosterBio’s breakthrough CliniControl™ hMSC manufacturing platform.
In addition, Senti will employ RoosterBio for external development of hMSC supply and expansion, including bioreactor scale-up and industrialised large-scale manufacturing unit operations.
RoosterBio is a privately-held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry. More details at www.roosterbio.com.
-- BERNAMA
No comments:
Post a Comment